Seeking Alpha

St. Jude Medical, Inc. (STJ)

  • Nov. 5, 2013, 2:54 PM
    • Bernstein downgrades St. Jude Medical (STJ -2.6%) to Market Perform from Outperform.
    • Analyst Derrick Sung still likes STJ's position in the CRM market, but with the stock up 60% YTD, doesn't see much in the way of multiple expansion going forward.
    • Specifically, Sung notes that the main components of the outperform thesis ("a lifting of the Riata/Durata overhang, a recovery in the ICD markets, and a reincarnation of the CardioMEMS opportunity") have "played out."
    | Nov. 5, 2013, 2:54 PM | Comment!
  • Oct. 16, 2013, 7:52 AM
    • "Our Q3 results demonstrate that we are successfully implementing our program to accelerate sales growth on a sustainable basis," St. Jude Medical (STJ) CEO Daniel Starks says, regarding the company's MRQ performance.
    • Stripping out currency impact, STJ's Q3 sales grew 3% Y/Y.
    • On a segment-by-segment basis (currency neutral): CRM sales were essentially flat at $682M, AF sales rose 7% to $235M, cardiovascular sales jumped 4% to $317M, and neuromodulationsales were up around 3% to $104M.
    • Outlook: Q4 EPS of $0.95-0.97 on revenue of $1.315B-1.395B versus consensus of $0.96/share on sales of $1.39B. For the full year: EPS of $3.72-3.74 on sales of $5.394-5.474B against consensus of $3.72/share and revenue of $5.45B. (PR)
    | Oct. 16, 2013, 7:52 AM | Comment!
  • Oct. 16, 2013, 7:32 AM
    • St. Jude Medical (STJ): Q3 EPS of $0.90 beats by $0.01.
    • Revenue of $1.34B (+1% Y/Y) beats by $0.02B. (PR)
    | Oct. 16, 2013, 7:32 AM | Comment!
  • Oct. 16, 2013, 12:05 AM
  • Oct. 15, 2013, 5:30 PM
  • Oct. 14, 2013, 7:56 AM
    • Cowen upgrades St. Jude Medical (STJ) to Market Perform from Underperform.
    • Price target is $53.
    • Earlier: STJ completes Nanostim acquisition.
    | Oct. 14, 2013, 7:56 AM | Comment!
  • Oct. 14, 2013, 7:11 AM
    • St. Jude Medical (STJ) has completed the acquisition of Nanostim, the developer of the world's only wireless pacemakers, for $123.5M upfront and a further $65M based on regulatory and sales goals.
    • St. Jude expects to soon introduce the pacemaker in select European markets after it received the EU's CE approval.
    • St. Jude first invested in Nanostim in 2011 and said in February this year that it intended to acquire the company. (PR)
    | Oct. 14, 2013, 7:11 AM | Comment!
  • Oct. 10, 2013, 9:45 AM
    • An FDA advisory panel sent a mixed message yesterday about the CardioMEMS Champion HF Pressure Measurement System, sending shares of St. Jude Medical (STJ -2.5%), part owner of CardioMEMS, lower.
    • Champion HF is an implantable device provides that provides daily pulmonary artery pressure measurements to guide physicians in their treatment of patients with congestive heart failure.
    • One panel member said it was impossible for the members to tie the daily measurements of the pulmonary artery to a decrease in hospitalizations or other important clinical outcomes; “We couldn’t connect the dots."
    | Oct. 10, 2013, 9:45 AM | Comment!
  • Oct. 4, 2013, 1:46 PM
    • St. Jude Medical (STJ +3.4%) rises to an all-time high on heavy volume.
    • Briefing documents from the FDA regarding an advisory panel meeting for CardioMEMS' Champion Heart Failure Monitoring System seem to suggest the regulator is more likely to approve the device this time around — or at least that's RBC and Leerink's reading. (full briefing documents)
    • "We think there's a few clauses in the conclusion where the FDA reviewers portray subtle inclinations," RBC's Glenn Novarro says.
    • Meanwhile, Leerink's Danielle Antalffy is already looking forward to an STJ deal for CardioMEMS: "We estimate [Champion HF] can ultimately contribute an incremental $0.25-$0.50 in EPS." (IBD)
    | Oct. 4, 2013, 1:46 PM | Comment!
  • Aug. 29, 2013, 11:34 AM
    • St. Jude Medical (STJ +0.6%) says it received CE Mark approval of its next-generation EnligHTN Renal Denervation System for treating patients with drug-resistant, uncontrolled hypertension.
    • The system features an advanced generator that delivers simultaneous ablations via a multi-electrode catheter, reducing total ablation time by more than 80% in comparison to the first generation system, from approximately 24 minutes to four minutes.
    • The new system will be on display during the 2013 European Society of Cardiology meeting from August 31 to September 3.
    | Aug. 29, 2013, 11:34 AM | Comment!
  • Aug. 19, 2013, 8:32 AM
    • St. Jude Medical (STJ) has bought Swiss-based Endosense for an initial $170M and up to $161M in milestone payments.
    • Endosense develops TactiCath, which allows physicians to monitor the amount of force they apply to the heart wall during a catheter ablation procedure to remove or stop a faulty electrical pathway.
    • "Force sensing is a tremendous advancement in cardiac ablation that will potentially improve safety and efficacy, likely becoming a standard for all cardiac ablations," says Dr Vivek Reddy of Mount Sinai Hospital in New York. (PR)
    | Aug. 19, 2013, 8:32 AM | Comment!
  • Aug. 15, 2013, 10:27 AM
    • St. Jude Medical (STJ -2%) slips this morning in spite of its announcement that the FDA has approved its MediGuide Enabled ablation catheters used to treat specific irregular heartbeats.
    • Adding insult to injury, the shares were also upgraded to Outperform this morning at Wells Fargo.
    | Aug. 15, 2013, 10:27 AM | Comment!
  • Jul. 30, 2013, 5:53 PM
    • St. Jude Medical, Inc. (STJ) declares $0.25/share quarterly dividend, in line with previous.
    • Forward yield 1.92%
    • Payable Oct. 31
    • For shareholders of record Sept. 30
    • Ex-div Sept. 26
    | Jul. 30, 2013, 5:53 PM | Comment!
  • Jul. 17, 2013, 7:59 AM
    More on St. Jude Medical (STJ +2.1%) Q2: net profit -53% to $115M, hurt by charges of $160M, primarily related to debt retirement. Adjusted net profit flat at $275M. Net sales also flat. Sales breakdown: Cardiac Rhythm Management -4% to $718M; Atrial Fibrillation +9% to $237M; Cardiovascular flat at $340M; neuromodulation +2% to $108M. Guidance: Q3 EPS of $0.88-0.90 vs consensus of $0.88; FY EPS of $3.70-3.73, increasing the lower range by $0.02 from prior forecast and vs analyst predictions of $3.69. (PR)
    | Jul. 17, 2013, 7:59 AM | Comment!
  • Jul. 17, 2013, 7:31 AM
    St. Jude Medical (STJ): Q2 EPS of $0.96 beats by $0.02. Revenue of $1.40B beats by $0.04B. (PR)
    | Jul. 17, 2013, 7:31 AM | Comment!
  • Jul. 17, 2013, 12:05 AM
    Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, FCFS, FRC, GWW, IGTE, MAT, MTB , NTRS, NVS, PNC, STJ, TXT, USB
    | Jul. 17, 2013, 12:05 AM | Comment!
STJ vs. ETF Alternatives
Company Description
St Jude Medical Inc develops, manufactures and distributes cardiovascular medical devices for global cardiac rhythm management, cardiovascular, atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain.